By Ben GlickmanBristol Myers Squibb said on Friday that its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The company's trial was evaluating the cancer-drug Opdivo and concurrent chemoradiotherapy, followed by Opdivo plus Yervoy, the brand name for a monoclonal antibody, in treating unresectable, locally advanced non-small cell lung cancer. The trial's primary endpoint was progression-free survival. Bristol Myers Squibb said it would fully evaluate the data and work with investigators to share results with the scientific community. Opdivo and certain combinations with Opdivo are approved treatments for eligible patients with non-small cell lung cancer.

Source: Wall Street Journal May 11, 2024 08:58 UTC